Keywords
oncological process
cancer
thrombotic complications
skeletal muscle in thrombosis
How to Cite
Abstract
Modern research has shown that cancer patients are at high risk of thrombotic complications, which worsen the results of anticancer treatment and occupy one of the leading places among the causes of death. Deep vein thrombosis of the lower extremities, as well as pulmonary embolism is the most dangerous complication of the cancer process in the body. The pathogenesis of hemostasiological paraneoplasia is based on the activation of both coagulation and vascular-platelet coagulation, which is provided by:disruption of the structural integrity and functional stability of the vascular endothelium by the cells of the tumor and cytokines; activation of platelets, which subsequently leads to their increased adhesion and aggregation; synthesis of procoagulants and fibrinolysis inhibitors; procoagulant activity of tumor-associated macrophages and activated peripheral blood monocytes. The aim of the study was to evaluate the structural changes of striated muscles and endothelial cells of the hemomicrocirculatory tract in deep vein thrombosis of the lower extremities of cancer patients. In order to detect changes in the muscular tissues of the lower extremity in oncopathology, scientists from I.Ya. Gorbachevsky Ternopil National Medical University conducted a light-optical histological and polarization study of skeletal muscle necropsies that died of cardiopulmonary shock in cancer patients. As a result of the assessment of structural changes of striated muscles and endothelial cells of the hemomicrocirculatory tract in deep vein thrombosis of the lower extremities of cancer patients, polarization microscopy showed significant contractural changes against the background of dyscirculatory changes. Given that the muscles of the lower extremities play a significant role in ensuring venous hemodynamics due to their contractile ability, these changes can be considered an important complementary link in the pathogenesis of venous insufficiency in patients with cancer and development of thrombotic complications in them. It should be noted that in this process an important role belongs to endothelial dysfunction. It is the damage of endothelial cells and "exposure of the bagal membrane" is the initial phase in the violation of microcirculation with the development of venule dystonia, interstitial and perivascular edema. At colon cancer against the background of hemodynamic disturbances expressed by degenerative damages of endotheliocytes with their desquamation, plethora of venules with dystonia of their gleam, interstitial and perivascular hypostasis there are heterogeneous displays of remodeling which are characterized by striated and contractural changes, homogenization of sarcoplasm with myocytolysis.
Keywords: phlebothrombosis, oncological process, cancer, thrombotic complications, skeletal muscle in thrombosis.
References
Barsam SJ, Patel R, Arya R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol. 2013;161(6):764–77. DOI: 10.1111/bjh.12314. PMID: 23560605.
Mishenina EB, Nevrozov VP, Oklei DV. Morfolohichne obhruntuvannia vynyknennia hostrykh venoznykh tromboziv [Morphological study of acute venous thrombosis]. Kharkivska khirurhichna shkola [Kharkiv Surgical School]. 2015;3(72):117–22. Available from: https://surgical-school.com.ua/index.php/journal/issue/view/13/3-2015-pdf [in Ukrainian].
Nepomniashchikh LM, Bakarev MA. Morfohenez metabolicheskikh povrezhdenii skeletnykh myshts [Morphogenesis of metabolic damage to skeletal muscle]. Moscow: Publishing house RAMN; 2005. 352 p. [in Russian].
Sivak VV, Timofiieva NV, Dynnyk OB et al., inventors; Patent Ukrainy No 25012 UA, G01N33/50. Sposib vyznachennia vilnotsyrkuliuiuchykh endotelialnykh klityn v krovi [Patent of Ukraine No 25012 UA, G01N33/50. A method for determining free-circulating endothelial cells in the blood]. 25 Jul 2007 [in Ukrainian].
Tsellarius YuH, Semenova LA, Himov RKh. Ranniie stadii eksperimentalnoho infarkta miokarda pri issledovanii opticheskimi metodami [Early stages of experimental myocardial infarction in the study of optical methods]. Arkhiv patolohii [Archive of Pathology]. 1976;38:47–52 [in Russian].
Shilova AN. Metody medikamentoznoi profilaktiki i lecheniia trombozov u onkolohicheskikh bolnykh, ikh vliianiie na rost i metastazirovaniie opukholei, na vyzhivaiemost bolnykh (obzor literatury) [Approaches for preventing and treating thrombosis in cancer patients, their influence on tumor growth and metastasis, and on survival of patients (literature review)]. Sibirskii onkolohicheskii zhurnal [Siberian Journal of Oncology]. 2012;2(50):79–83 [in Russian].
Bodnar PYa, Bodnar YaYa et al. Patomorfolohichni zminy velykoi pidshkirnoi veny pry khronichnii krytychnii ishemii nyzhnikh kintsivok [Pathomorphological changes of the great saphenous vein in chronic critical ischemia of the lower extremities]. Proceedings of the scientific-practical conf. Morfolohiia na suchasnomu etapi rozvytku nauky – Morphology at the present stage of development of science, 5–6 Oct 2012; Ternopil. Ternopil: TSMU; 2012. P. 20–3. [In Ukrainian].
Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78(1):126–32. PMID: 9198141.
Donati MB, Poggi A. Malignancy and haemostasis. Brit J Haematol. 1980;44:173–84.
Hillen HF. Thrombosis in cancer patients. Ann Oncol. 2000;11 Suppl 3:273–76. DOI: 10.1093/annonc/11.suppl_3.273. PMID: 11079152.
Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–18. DOI: 10.1182/blood-2013-04-460147. PMID: 23908470.
Goryainova NV. Znacheniie komorbidnosti dlia stratifikatsii lecheniia ostrykh miieloidnykh leikozov u vzroslykh [The importance of comorbidity for stratification of treatment of acute myeloid leukemia in adults]. ScienceRise. 2015;6(4(11)):68–72. DOI: 10.15587/2313-8416.2015.45466. [In Russian].
Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Thromb Haemost.1993;70(3):540–2. PMID: 8259561.
Kobayashi T. [Prophylaxis and treatment of venous thromboembolism based on Japanese clinical guides]. Rinsho Ketsueki. 2017;58(7):875–82. DOI: 10.11406/rinketsu.58.875. PMID: 28781287. [In Japanese].
Lee AY. Overview of VTE treatment in cancer according to clinical guidelines. Thromb Res. 2018;164 Suppl 1:S162–7. DOI: 10.1016/j.thromres.2018.01.002. PMID: 29307469.
Kamalov IA, Kurtasanov RS. Vyiavleniie prokoahuliantnoi aktivnosti zlokachestvennykh novoobrazovanii [Detection of malignant neoplasms procoagulant activity]. Kazanskii meditsinskii zhurnal [Kazan Medical Journal]. 2016;97(2):212–5. DOI: 10.17750/KMJ2016-212. [In Russian].
Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol. 2001;73(2):145–50. DOI: 10.1007/BF02981930. PMID: 11372724.
Verso M, Franco L, Giustozzi M, Becattini C, Agnelli G. Treatment of venous thromboembolism in patients with cancer: Whats news from clinical trials? Thromb Res. 2018;164(1):S168–71. DOI: 10.1016/j.thromres.2018.01.031.